Sorafenib (S) in combination with irinotecan (I) as a treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS mutation (mt) as second line or later: Interim analysis results of multicenter phase II part trial (NEXIRI)

Article de revue

Avec comité de lecture

M. Ychou, E. François, S. Thézenas, P. Laurent-Puig, O. Bouche, A. Adenis, J. Bennouna, E. Assenat, F. Portales et E. Samalin

Journal of clinical oncology, Vol.28(15_suppl), pp.e14022-e14022

20/05/2010

Résumé

Abstract only

1 Consultations de la notice

Titre: Sorafenib (S) in combination with irinotecan (I) as a treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS mutation (mt) as second line or later: Interim analysis results of multicenter phase II part trial (NEXIRI)
Créateurs - sans rôle: M. Ychou
E. François
S. Thézenas
P. Laurent-Puig
O. Bouche
A. Adenis
J. Bennouna
E. Assenat
F. Portales
E. Samalin
Détails de publication: Journal of clinical oncology, Vol.28(15_suppl), pp.e14022-e14022
Identifiants: 99140051509311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article